MENU
+Compare
PCRX
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$26.74
Change
-$0.24 (-0.89%)
Capitalization
1.36B

PCRX Pacira BioSciences Forecast, Technical & Fundamental Analysis

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients... Show more

PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PCRX with price predictions
Jun 04, 2025

PCRX in upward trend: price rose above 50-day moving average on May 15, 2025

PCRX moved above its 50-day moving average on May 15, 2025 date and that indicates a change from a downward trend to an upward trend. In of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on PCRX as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PCRX just turned positive on June 02, 2025. Looking at past instances where PCRX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where PCRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PCRX broke above its upper Bollinger Band on June 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.557) is normal, around the industry mean (62.170). P/E Ratio (32.742) is within average values for comparable stocks, (89.614). PCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (2.244) is also within normal values, averaging (19.131).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PCRX is expected to report earnings to rise 10.15% to 68 cents per share on August 05

Pacira BioSciences PCRX Stock Earnings Reports
Q2'25
Est.
$0.68
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.20
The last earnings report on May 08 showed earnings per share of 62 cents, beating the estimate of 58 cents. With 299.87K shares outstanding, the current market capitalization sits at 1.36B.
A.I. Advisor
published General Information

General Information

a manufacturer of injectable therapeutic products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
5401 West Kennedy Boulevard
Phone
+1 813 553-6680
Employees
713
Web
https://www.pacira.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSDVX20.02N/A
N/A
BlackRock Equity Dividend Svc
WWSIX21.75N/A
N/A
TETON Westwood SmallCap Equity I
IRLUX42.21N/A
N/A
Voya Russell Large Cap Index Port S2
CXXRX22.12N/A
N/A
Columbia Small Cap Index Inst2
AUXIX31.45-0.08
-0.25%
Auxier Focus Institutional

PCRX and Stocks

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
+2.20%
ELAN - PCRX
32%
Poorly correlated
-0.15%
TEVA - PCRX
28%
Poorly correlated
+1.92%
ACET - PCRX
27%
Poorly correlated
+1.54%
SNDL - PCRX
26%
Poorly correlated
+0.78%
NBIX - PCRX
25%
Poorly correlated
-0.38%
More